Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2025-04-28 Board/Management Inform…
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Change in designation - Senior Management Personnel of the Company
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding a change in senior management personnel, specifically a change in designation of Mr. Kushal Suri within the company. It references compliance with SEBI Listing Regulations and provides details about the appointment and profile of the individual. There is no financial data, no report attached or referenced as being published, and the content is focused solely on management changes. This fits the category of Board/Management Information (MANG). The document length is 4087 characters, which is relatively short but contains substantive information about management change, not just an announcement of a report publication or a regulatory filing. Therefore, the correct classification is MANG with high confidence.
2025-04-28 English
Please find attached the file
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding the formation of a wholly owned subsidiary in Dubai, UAE. It references Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, which pertains to disclosure of material events. The document includes details about the subsidiary's incorporation, shareholding, and business purpose. There are no financial statements, earnings data, or management discussion of financial results. The document is an announcement of a corporate event (formation of a subsidiary) rather than a financial report or detailed presentation. This fits the category of Capital/Financing Update (CAP), as it relates to changes in the company's capital structure through the creation of a subsidiary and share subscription. The document length is 4667 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the appropriate classification is CAP with high confidence.
2025-04-28 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding the formation of a wholly owned subsidiary in Dubai, UAE. It references Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, which pertains to disclosure of material events. The document includes details about the subsidiary's incorporation, shareholding, and business purpose. There are no financial statements, earnings data, or management discussion of financial results. The document is an announcement of a corporate event (subsidiary formation) rather than a financial report or detailed presentation. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as incorporation of subsidiaries.
2025-04-28 English
File Attached
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding the launch of four new pharmaceutical products by Morepen Laboratories. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events or information by listed companies. The content focuses on announcing new product launches, detailing product features, market strategy, and company positioning. There is no financial data, quarterly or annual results, management discussion, or audit information presented. The document is an announcement of a material event (product launch) rather than a financial report or regulatory filing of financial results. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2025-04-24 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding the launch of four new pharmaceutical products by Morepen Laboratories. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events or information by listed companies. The content focuses on announcing new product launches, detailing product features, manufacturing capabilities, and strategic business plans. There is no financial data, quarterly or annual results, management discussion, or audit information presented. The document is an announcement of a material event (product launch) rather than a financial report or regulatory filing of financial results. Therefore, it fits best under the category of a Regulatory Filing (RNS), which covers general regulatory announcements and disclosures that do not fit into other specific categories.
2025-04-24 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding a change in the name of a subsidiary company from 'Morepen Medtech Limited' to 'Morepen Medipath Limited'. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an announcement of a corporate event (name change) rather than a financial report, management update, or other detailed filing. The document length is short (1668 characters), and it serves as an intimation to the stock exchanges. This fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement that does not fit into more specific categories.
2025-04-17 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.